Safety, Tolerability, and Pharmacokinetics of Mufemilast, a PDE4 Inhibitor, in Healthy Participants: A First‐in‐Human Phase 1 Study

Documenti analoghi

• Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants
  di: Jo Collier, et al.
  Pubblicazione: (2026)
• Comparability of Elezanumab Safety, Tolerability, and Pharmacokinetics in Healthy Japanese, Chinese, and White Participants
  di: Hari V. Kalluri, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, in Healthy Chinese Participants
  di: Jingjing Wang, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants
  di: Alessandra Cipriano, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
  di: Assem el Baghdady, et al.
  Pubblicazione: (2024)